Skip to main content

Table 3 List of all active, completed or terminated clinical trials of mRNA antibodies and immunomodulators in cancer therapy

From: mRNA therapeutics in cancer immunotherapy

Sponsor

Therapy (delivery route)

Indication

ClinicalTrial.gov identifier (phase, allocation)

Combination

Opened

Status

Antibodies

 Duke University

DC with GITRL/anti-CTLA-4 mAb mRNA (i.n.)

Metastatic melanoma

NCT01216436 (I)

Melanoma TAA mRNA transfected DCs

2010

Terminated (lack of personnel)

Immunomodulators

 Cytokines

  Medimmune LLC, Moderna TX Inc.

LNP with IL-12 mRNA (i.t.)

Solid tumors

NCT03946800 (I)

Durvalumab

2019

Recruiting

  Moderna TX Inc., AstraZeneca

LNP with OX40L, IL-23 and IL-36γ mRNA (i.t.)

Relapsed/refractory solid tumor malignancies or lymphoma, TNBC, HNSCC, Non-Hodgkin lymphoma, urothelial cancer

NCT03739931 (I)

Durvalumab

2018

Recruiting [182]

  Sanofi, BioNTech SE

scIL-12, IL-15sushi, IFNα and GM-CSF mRNA (i.t.)

Metastatic neoplasms

NCT03871348 (II, non-randomized)

Cemiplimab

2019

Recruiting

 Stimulatory ligands and receptors

  eTheRNA Immunotherapies Nv.

TriMix (CD70, CD40L, caTLR4) mRNA and TAA mRNA (i.n.)

Melanoma

NCT03394937 (I)

None

2018

Recruiting

  Moderna TX Inc.

LNP-OX40L mRNA (i.t.)

Relapsed/refractory solid tumor malignancies or lymphoma, ovarian cancer

NCT03323398 (I/II, non-randomized)

Durvalumab

2017

Recruiting

  Universitair Ziekenhuis Brussel, eTheRNA Immunotherapies Nv.

TriMix (CD70, CD40L, caTLR4) mRNA (i.t.)

Early resectable breast cancer

NCT03788083 (I)

None

2018

Recruiting

  1. From ClinicalTrial.gov (keywords: cancer AND mRNA AND immunomodulator OR cytokine OR co-stimulator OR antibody) on Dec 1, 2020 and PubMed literature search. ca constitutively active, CD40L CD40 ligand, CTLA-4 cytotoxic T-lymphocyte-associated protein 4, DC dendritic cell, GITRL glucocorticoid-induced tumor necrosis factor receptor family-related protein ligand, GM-CSF granulocyte-macrophage colony stimulating factor, HNSCC head and neck squamous cell carcinoma, i.n. intranodal, i.t. intratumoral, IFN interferon, IL interleukin, LNP lipid nanoparticle, mAb monoclonal antibody, OX40L OX40 ligand, sc single-chain, TAA tumor-associated antigen, TLR toll-like receptor, TNBC triple-negative breast cancer